1. Home
  2. SGRP vs MBRX Comparison

SGRP vs MBRX Comparison

Compare SGRP & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SPAR Group Inc.

SGRP

SPAR Group Inc.

HOLD

Current Price

$0.61

Market Cap

14.5M

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$2.58

Market Cap

12.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGRP
MBRX
Founded
1967
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.5M
12.8M
IPO Year
1996
2016

Fundamental Metrics

Financial Performance
Metric
SGRP
MBRX
Price
$0.61
$2.58
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
39.6K
88.0K
Earning Date
03-31-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$136,104,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.25
52 Week High
$1.41
$7.98

Technical Indicators

Market Signals
Indicator
SGRP
MBRX
Relative Strength Index (RSI) 45.37 53.59
Support Level $0.50 $0.39
Resistance Level $0.83 $2.77
Average True Range (ATR) 0.06 0.14
MACD 0.01 0.04
Stochastic Oscillator 63.12 64.41

Price Performance

Historical Comparison
SGRP
MBRX

About SGRP SPAR Group Inc.

SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. The company provides five principal types of services: Merchandising, Marketing and Category Management, Remodel and Retail Transformation, Assembly and Installation, Fulfilment and Distribution, and Business Analytics and Insights. It operates in two segments, namely the U.S. and Canada, with the majority of the revenues deriving from the U.S. segment.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: